FDA Approval Alert: The Need-to-Know | Durvalumab/Chemotherapy in dMMR Advanced Endometrial Cancer

In June 2024, the FDA approved durvalumab in combination with carboplatin and paclitaxel followed by durvalumab maintenance for adults with mismatch repair deficient primary advanced or recurrent endometrial cancer.

Data from the DUO-E trial support the FDA approval of durvalumab/chemotherapy for those with primary advanced or recurrent dMMR endometrial cancer.
FDA Approves Durvalumab/Chemo in dMMR Advanced Endometrial Cancer
Article
Jun 14, 2024 8:48 PM
Data from the DUO-E trial support the FDA approval of durvalumab/chemotherapy for those with primary advanced or recurrent dMMR endometrial cancer.